Saturday, November 6, 2021
- 8:30AM-10:30AM
-
Abstract Number: 0229
The Effects of Self-efficacy on Fatigue and Pain Interference in Black Women with Systemic Lupus Erythematosus: The Role of Depression, Age, and Education
Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)- 8:30AM-10:30AM
-
Abstract Number: 0121
The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression
Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)- 8:30AM-10:30AM
-
Abstract Number: 0296
The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US
Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)- 8:30AM-10:30AM
-
Abstract Number: 0232
The Impact of Deucravacitinib on Health-Related Quality of Life Measured by the Short Form Health Survey 36-Item Questionnaire: Analysis of a Phase 2 Trial in Patients with Active PsA
Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)- 8:30AM-10:30AM
-
Abstract Number: 0238
The Impact of Preeclampsia on Pregnancies and Infants of Women with Rheumatic Disease
Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)- 8:30AM-10:30AM
-
Abstract Number: 0336
The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)- 8:30AM-10:30AM
-
Abstract Number: 0158
The Influence of Age on the Prevalence of Inflammatory and Post-inflammatory MRI Lesions in the Sacroiliac Joints of Patients with and Without Axial Spondyloarthritis
Imaging of Rheumatic Diseases Poster (0149–0182)- 8:30AM-10:30AM
-
Abstract Number: 0025
The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis
RA – Etiology & Pathogenesis Poster (0011–0045)- 8:30AM-10:30AM
-
Abstract Number: 0036
The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects
RA – Etiology & Pathogenesis Poster (0011–0045)- 8:30AM-10:30AM
-
Abstract Number: 0348
The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)- 8:30AM-10:30AM
-
Abstract Number: 0217
The OMERACT Knee Inflammation MRI Scoring System: Validation of Quantitative Methodologies and Tri-compartmental Overlays by Comparison with the MRI Osteoarthritis Knee Score
Osteoarthritis – Clinical Poster I (0210–0224)- 8:30AM-10:30AM
-
Abstract Number: 0377
The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)- 8:30AM-10:30AM
-
Abstract Number: 0266
The Psychosocial Impact of the COVID-19 Pandemic on the Rheumatology Patient Experience
Psychology/Social Sciences Poster (0266–0267)- 8:30AM-10:30AM
-
Abstract Number: 0356
The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease